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6 Present address: Great Lakes Pharmaceuticals, BeaFabH (b-ketoacyl-acyl carrier protein synthase III) is unique in that it initiates fatty acid biosynthe-
sis, is inhibited by long-chain fatty acids providing means for feedback control of the process, and
dictates the fatty acid proﬁle of the organism by virtue of its substrate speciﬁcity. We report the
crystal structures of bacterial FabH enzymes from four different pathogenic species: Enterococcus
faecalis, Haemophilus inﬂuenzae, Staphylococcus aureus and Escherichia coli. Structural data on the
enzyme from different species show important differences in the architecture of the substrate-
binding sites that parallel the inter-species diversity in the substrate speciﬁcities of these enzymes.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Increased antimicrobial drug resistance in organisms such as
methicillin resistant Staphylococcus aureus (MRSA) has necessi-
tated the search for new therapeutic agents against these and other
pathogens [1]. One of the keys to overcoming this problem is to
identify a compound with a novel mode of action toward a new
target enzyme. The bacterial fatty acid biosynthesis (fab) pathway
has been shown to be essential for cell growth [2–5] and may pro-
vide us with one such target.
All organisms synthesize fatty acids via a conserved cycle of
condensation, reduction, dehydration and reduction of carbon–
carbon bonds [3], but mammals encode a single multifunctional
multi-domain enzyme that hosts the active site for each of the
synthetic steps on a different domain. This is referred to as the
type I pathway. Bacteria, on the other hand, follow the type II
pathway where each enzymatic activity is found on a distinct
protein [6]. The protein sequences and the enzymatic active siteschemical Societies. Published by E
bal Research & Development,
A. Fax: +1 858 678 8293.
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chwood, OH 44122, USA.of the two types bear little resemblance to each other leading us
to believe that it should be possible to design speciﬁc and potent
inhibitors of enzymes from the type II fab pathway, with little or
no cross-reactivity with the type I enzyme [6].
Excellent reviews of the fab cycle can be found elsewhere [3,6].
FabH catalyzed condensation of malonyl–acyl carrier protein (ACP)
with acetyl-CoA to form b-ketobutyryl-ACP is the initiation step of
straight chain saturated fatty acid biosynthesis. In addition to
being the regulatory enzyme for the fab cycle, the fatty acid proﬁle
of an organism is determined by the substrate speciﬁcity of its
FabH enzyme [5,7]. Escherichia coli, wherein straight chain fatty
acids are predominant, acetyl-CoA and propionyl-CoA are the pre-
ferred substrates for FabH [8]. On the other hand, in Bacillus subtilis
and Streptomyces glaucescens, which are known to produce both
straight and branched chain fatty acids, FabH can use branched
chain acyl-CoA in addition to straight chain acyl-CoA as substrates
[7]. The molecular basis for this substrate speciﬁcity of the enzyme
is not clear though bacterial FabH from various species have been
structurally characterized [9–14].
Here we present six structures of FabH enzymes from patho-
gens Enterococcus faecalis, Haemophilus inﬂuenzae, Staphylococcus
aureus and E. coli. The analysis of available FabH structures shows
subtle differences in the active site architectures of these enzymes
from Gram-positive and Gram-negative organisms. These differ-
ences parallel the differences seen in the substrate speciﬁcities of
these enzymes and hence provide a basis for not only explaining
experimentally determined substrate speciﬁcities, but also providelsevier B.V. All rights reserved.
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can be predicted using the sequence analysis of their FabH en-
zymes. Two of the structures presented here were determined in
complex with novel inhibitors shedding light on the mechanism
of molecular recognition. These co-crystal structures identify the
interactions between the protein and the compounds that can be
potentially developed into high afﬁnity inhibitors using the ob-
served principles of molecular recognition.
2. Materials and methods
2.1. Expression, puriﬁcation and crystallization of FabH
Full-length E. coli, E. faecalis, S. aureus and H. inﬂuenzae FabH pro-
teins were cloned into pET expression vectors (Novagen) with an
N-terminal His-tag (pET28) as well as in tagless version (pET30).
All proteins were expressed in E. coli strain BL21 (DE3) (Invitro-
gen). Harvested cells containing his-tagged FabH were lysed by
sonication in 20 mM Tris pH 7.6, 5 mM imidazole, 0.5 M NaCl and
centrifuged at 20 000 rpm for 30 min. The supernatant was applied
to Ni-NTA agarose column (Qiagen), washed, and eluted using a
5–500 mM imidazole gradient over 20 column volumes. Eluted
protein was dialyzed against 20 mM Tris pH 7.6, 1 mM DTT, and
100 mM NaCl. Puriﬁed FabH were concentrated up to 2 mg/ml
and stored at 80 C in 20 mM Tris pH 7.6, 100 mM NaCl, 1 mM
DTT, and 20% glycerol for enzymatic assays or concentrated up to
20 mg/ml for crystallization trials.
Harvested cells expressing tagless FabH were sonicated in
25 mM Tris 8.0, 20 mM NaCl, 2 mM DTT, 1 mM EDTA, 50 mM DVT,
and 0.5 ml (per 100 ml lysate) protease inhibitor cocktail (Roche).
The crude lysate was centrifuged at 20,000 rpm for 30 min and the
soluble fraction was separated by anion-exchange chromatography
(HiPrep 16/10 Q XL, Amersham Pharmacia Biotech (APB)) using a
0–1 M NaCl gradient over 10 column volumes. Protein fractions
were checked by SDS–PAGEand appropriate fractionswere dialyzed
against 25 mM Tris 8.0, 2 mM DTT, and 50 mM DVT. Dialyzed pro-
tein was loaded onto a 10 ml Source Q-15 (APB) and further sepa-
rated by anion-exchange chromatography using a 0–500 mM NaCl
gradient over 20 column volumes. Protein fractions were checked
by SDS–PAGEand FabHcontaining fractionswere pooled and loaded
onto an 8 ml hydroxyapatite column (Bio-Rad) and eluted with 0–
250 mM gradient of a pH 8.0 potassium phosphate buffer over 15
column volumes. FabH containing fractions concentrated up to
2 mg/ml and stored at 80 C in 20 mM Tris pH 7.6, 100 mM NaCl,
1 mM DTT, and 20% glycerol for enzymatic assays or concentrated
up to 20 mg/ml for crystallization trials.
All crystals were obtained by vapor diffusion using 20 mg/ml
protein solution in the hanging drop setups at 15 C. N-terminally
His-tagged E. coli FabH was crystallized with 12% PEG 3350, 5 mM
calcium acetate, 0.1 M HEPES, pH 7.5, 2 mM TCEP and 1% DMSO.
The CoA bound structure of E. faecalis FabH was obtained using
the tagless protein with two point mutations, A192T and N253S,
which were cloning artifacts. These mutations have no impact on
the protein structure as inferred from comparison with the com-
pound 13a bound E. faecalis FabH structures obtained with the
wild-type sequence. The crystallization condition consisted of
25% PEG 3350, 0.1 M HEPES, 0.125 M magnesium sulfate, and
1.5% DMSO. The co-crystal structure of E. faecalis FabH with bound
compound 13a was obtained using the N-terminally His-tagged
protein. The crystallization conditions consisted of 0.2 M lithium
sulfate, 0.1 M Bis-Tris, pH 6.5, 25% PEG3350. The structure of E.
faecalis FabH with bound compound 23i was determined using
the tagless protein with two speciﬁc surface mutations (D36A,
E37A, which improved crystallizability) crystallized with 25% PEG
3350, 0.2 M ammonium sulfate and 0.1 M Bis–Tris, pH 5.5. H. inﬂu-
enzae FabH structure was obtained using N-terminally tagged pro-tein and crystallization condition consisting of 35% PEG 4000,
0.4 M ammonium acetate, 0.1 M sodium citrate, pH 6 and 15% glyc-
erol. Tagless S. aureus FabH gave crystals with 2 M sodium formate,
0.1 M sodium acetate, pH 4.6.
2.2. Enzyme inhibitors
Biochemical screening of 2500 select compound library
esulted in 27 hits with IC50 < 10 lM. Of the four structurally
diverse series identiﬁed, the benzoylamino-benzoic acid series
of compounds was chosen for optimization. Two of these com-
pounds, 2-(4-bromo-3-diethylsulfamoyl-benzoylamino)-benzoic
acid (13a) and 2-[4-(3,5-dimethyl-piperidin-1-yl)-3-phenoxy-
benzoylamino]-benzoic acid were synthesized at Quorex as
described elsewhere [15]. The compound 13a showed an IC50
of 1.6 lM and 23i an IC50 of 0.27 lM against E. faecalis enzyme.
2.3. Data collection and structure determination
All data were collected at 110 K using MAR image plate and
rotating anode X-ray generator. Crystals were frozen in synthetic
mother liquor with 25% glycerol. Data were integrated, reduced
and scaled using the HKL program suite. CNX was used for molec-
ular replacement and reﬁnement of structures. Structure of the
E. coli FabH was ﬁrst determined by molecular replacement using
the 1.8 Å published structure of the same protein (PDB ID: 1EBL)
[10] as the starting model. All the subsequent structures were
determined by molecular replacement, using E. coli FabH structure
as the starting model.
2.3.1. Accession codes
The coordinates for structures solved in this study have been
deposited in the Protein Data Bank with ID codes 3IL3, 3IL4, 3IL5,
3IL6, 3IL7 and 3IL9.
3. Results and discussion
3.1. FabH structures
Including the structures reported here (Table 1), we have crystal
structures of the FabH enzyme from eight different bacterial spe-
cies, two of which are Gram-positive organisms (E. faecalis and
S. aureus [11]) and ﬁve Gram-negative (E. coli [10,12], H. inﬂuenzae,
A. aeolicus (PDB ID: 2EBD), T. thermophilus (PDB ID: 1UB7) and
B. pseudomallei (PDB ID: 3GWE));M. tuberculosis [13,14] falls under
neither Gram classiﬁcation. As has been noted earlier [12], the
FabH monomer has internal pseudo-symmetry in its structure sug-
gestive of a gene duplication event some time during its evolution.
Based on this symmetry, the structure can be divided into N-termi-
nal and C-terminal domains. However, there is barely any se-
quence similarity between the two domains of the same protein.
The inter-domain structural divergence between N- and C-termi-
nal domains within the FabH enzyme is most pronounced in the
ﬁrst loop (L1 of the N-terminal domain and L9 of the C-terminal
domain, refer to Davies et al. [10] for nomenclature) and the last
one (L7 of the N- and L15 of the C-terminal domain). These are also
functional regions of these proteins.
E. faecalis FabH structure presented here has four molecules in
the asymmetric unit. One of the molecules has good quality resid-
ual density to allow modeling of a bound acetyl-CoA molecule
(Fig. 1). Our E. coli and S. aureus FabH structures show residual den-
sity in the active site cleft that is uninterpretable. The active site
cysteine in the E. coli enzyme, Cys112, is doubly oxidized to cys-
teine sulﬁnic acid. In contrast, H. inﬂuenzae enzyme structure
shows that Cys112 is acetylated with no suggestion of an entrained
small molecule in the active site.
Fig. 1. Stereo drawings of acetyl CoA recognition by E. faecalis FabH. (a) 3 Å resolution Fo  Fc difference electron density map contoured at 3r (blue) and 5r (red)
superimposed on the ﬁnal reﬁned model of acetyl CoA. (b) Details of the acetyl CoA binding.
Table 1
Crystallographic data and reﬁnement statistics.
E. coli FabH E. faecalis FabH in complex with H. inﬂuenzae FabH S. aureus FabH
Acetyl CoA 13a 23i
Data collection
Space group P212121 P21 P21 P3221 P6522 P212121
Unit cell (Å) 64.1, 66.9, 161.5 66.8, 93.3, 104.3 66.6, 85.0, 114.4 119.3, 119.3, 68.9 68.2, 68.2, 277.7 55.9, 93.4, 109.6
b = 93.9 b = 98.5
Resolution (Å) 1.85 3.0 2.6 2.5 2.7 2.6
Observations 421 174 83 680 144 843 101 558 54 436 70 206
Unique reﬂections 59 560 25 403 38 358 19 811 10 562 18 210
Rsym 0.063 (0.449) 0.096 (0.229) 0.12 (0.338) 0.073 (0.361) 0.04 (0.175) 0.152 (0.361)
I/r 13.2 (3.1) 9.9 (4.6) 9.1 (3.1) 11.9 (4.3) 28.9 (8.7) 9.4 (3.4)
Completeness 0.992 (0.979) 0.99 (0.967) 0.986 (0.973) 0.999 (0.995) 0.924 (0.714) 0.997 (0.971)
Reﬁnement
R factor 0.186 0.196 0.194 0.185 0.232 0.195
Rfree 0.216 0.270 0.265 0.219 0.314 0.264
RMSD
Bond length (Å) 0.005 0.008 0.008 0.007 0.008 0.007
Bond angle () 1.3 1.3 1.4 1.3 1.4 1.3














Fig. 2. Benzoylamino-benzoic acid derivatives that inhibit FabH enzymatic activity.
Fig. 3. Molecular recognition of the small molecule inhibitors by E. faecalis FabH. Some
shown. Carboxylate of the benzoic acid group makes hydrogen-bonding contacts with t
2942 K.S. Gajiwala et al. / FEBS Letters 583 (2009) 2939–2946We obtained two co-crystal structures of E. faecalis FabH in com-
plex with benzoylamino-benzoic acid derivatives, 2-(4-bromo-3-
diethylsulfamoyl-benzoylamino)-benzoic acid (13a) and 2-[4-
(3,5-dimethyl-piperidin-1-yl)-3-phenoxy-benzoylamino]-benzoic
acid (23i) (Fig. 2) that show reasonable inhibition of the enzyme
[15]. The binding modes of the two are essentially identical, with
the compounds binding as far into the active site cleft as physically
possible (Fig. 3); they make 3.5 Å van der Waal’s contact with Ca
atom of Gly313 at the cleft ﬂoor. The benzoic acid group occupies
the deep end of the CoA binding site, in close proximity to the cat-
alytic triad. The phenyl ring of the benzoic acid makesr–p interac-
tion with Phe312, the residue that plays a signiﬁcant role in
deﬁning the shape of the binding site, and probably the substrate
speciﬁcity of the enzyme (see below). The amide N of the benzoyla-
mino group makes intra-molecular hydrogen-bonding interaction
with the carboxylate of the benzoic acid group. The carbonyl O of
the benzoylamino group, on the other hand is within hydrogen-
bonding interaction of the backbone N of Phe224. The phenyl ring
of the benzoylamino group is facing the solvent exposed entranceof the interactions between the protein and the compound 13a (a) or 23i (b) are
he active site residues His250 and Asn280, shown by the dashes.
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interactions with the protein can be found elsewhere [15].
3.2. Cis-peptide bonds
Two residues are found to have cis-peptide bonds in the FabH
structures from all four species reported here. These are Pro93
(and its equivalent Pro88 in S. aureus, H. inﬂuenzae and E. coli)
and Leu316 (Leu302 in S. aureus, Trp307 in H. inﬂuenzae and
Phe308 in E. coli) of E. faecalis protein. These two residues are far
apart in the primary sequence and the tertiary structure of a single
molecule. However, within the functional dimer, these two cis-
peptides from two different molecules are not only brought in
the immediate neighborhood of each other by virtue of dimeriza-
tion, but are also close to, but not in the immediate vicinity of,
the active site cleft. Dimerization brings N-terminal sequence
neighbor of the cis-Pro (Met92 in E. faecalis, Tyr87 in H. inﬂuenzae
and Phe87 in S. aureus and E. coli) close to the active site Cys, there-
by contributing to the formation of the substrate-binding cleft of
the dimeric partner.
3.3. Substrate speciﬁcities and differences in the substrate-binding
sites of FabH from different species
Despite wide range of pairwise sequence similarities (28.9–
66.2%), substrate-binding sites of FabH from various species are
remarkably well conserved, at least in terms of the sequence
(Fig. 4). We have identiﬁed 22 residues that make up the large
CoA binding tunnel, at the base of which are located the active site
residues. Fifteen of these 22 residues are very highly conserved in
all organisms irrespective of their Gram classiﬁcation. (Burkholde-Fig. 4. Sequence analysis of the residues constituting the FabH/ZhuH substrate-binding s
for FabH. The residue numbering on the top refers to the E. faecalis FabH; the number
according to the Gram classiﬁcation of the bacteria: the top group is for Gram-positive,
under neither. Residues highlighted in gray show some variability, other are largely con
binding site. They are highlighted according to the shape they force on the substrate-bind
Streptococcus pyogenes; Spn – Streptococcus pneumoniae; Ban – Bacillus anthracis; Lmo – Li
– Salmonella typhimurium; Ype – Yersinia pestis; Hpy – Helicobacter pylori; Vco – Vibrio ch
thermophilus; Aae – Aquifex aeolicus; Hin – Haemophilus inﬂuenzae; and Eco – Escherichiaria pseudomallei enzyme is an exception; we do not understand
the greater variation in its sequence.) At the remaining 7 positions,
few sequences show substitutions and, for the most part, these are
highly homologous substitutions. Yet based on the crystal struc-
tures the three-dimensional shapes of the acetyl-CoA binding cleft
in FabH enzymes from different species seem to differ signiﬁcantly
more near the base of the cleft than one could predict comparing
just the amino acid sequences, primarily due to different rotamer
conformations taken by a single sidechain near the ﬂoor of the
active site cleft (Fig. 5).
These differences in structures arise from the different rotamer
conformations taken by a mostly conserved Phe (Phe312 in E. fae-
calis FabH and its equivalent in the enzymes from other species) at
the base of the CoA binding cleft. We present strong evidence sug-
gestive of two classes of binding sites based on the type of fatty
acids synthesized by the organisms. Side chains Phe312 of E. faecal-
is, Phe298 of S. aureus and Tyr304 of M. tuberculosis FabH are
pointed inside the active site cleft of the enzyme, thereby decreas-
ing the size of the cleft. The rotamer adopted by the Phe/Tyr of the
enzyme in Gram-positive organisms is a relatively rare one (fre-
quency of occurrence 13% [16]), and is probably associated with
an energetic cost that is likely compensated elsewhere. The
Gram-negative organisms E. coli and H. inﬂuenzae on the other
hand, have the equivalent Phe side-chains (Phe304 and Phe303,
respectively) oriented in the opposite direction so as to be within
the hydrophobic core of the protein (Fig. 5). The sidechain rotamer
here is a relatively higher frequency (33% occurrence [16]) and
hence lower energy one. As a result, these organisms have FabH
active site clefts that are signiﬁcantly bigger than inM. tuberculosis
or the Gram-positive E. faecalis and S. aureus FabH. These speciﬁc
rotamer conformations are forced by the residue that is a layerite. Except the last sequence, which is for Streptomyces ZhuH enzyme, all others are
ing on the bottom refers to the E. coli protein. The sequences have been grouped
the bottom group is for the Gram-negative organisms; the one in the middle falls
served. The last two residues in the sequences do not contribute to the substrate-
ing site. Abbreviations: Efa – Enterococcus faecalis; Sau – Staphylococcus aureus; Spy –
steria monocytogenes; Mtu –Mycobacterium tuberculosis; Rri – Rickettsia rickettsii; Sty
olerae; Nme – Neisseria meningitides; Bps – Burkholderia pseudomallei; Tth – Thermus
coli.
Fig. 5. Illustration of the structural consequences of identities of residues at positions equivalent to Phe226 and Val231 of E. faecalis protein on the rotamer conformation of
the equivalent of Phe312, which dramatically inﬂuences the pocket size and hence the compound binding. In all (a–d) panels, Phe226, Val231 and Phe312 from E. faecalis
FabH are shown in red. The view on the left shows part of bound compound 13i. Each of the four panels shows two orthogonal views. The equivalent residues shown in yellow
(and labeled on the right hand panels) are from (a) E. coli, (b) H. inﬂuenzae, (c) S. aureus and (d) T. thermophilus FabH. Panel (d) also shows equivalent residues from M.
tuberculosis FabH in blue.
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faecalis FabH, this residue is Phe226, which is located right behind
Phe312 in the hydrophobic core of the enzyme. The equivalent res-
idue in S. aureus is Phe209 and in M. tuberculosis Trp215. However
in the Gram-negative E. coli and H. inﬂuenzae FabH, the residues
(equivalent to Phe226 of E. faecalis FabH) are Val215 and Leu214,
respectively, which have much smaller side chains. Consequently,
not only Phe304 in E. coli and Phe303 in H. inﬂuenzae enzymes have
the freedom to orient their side chains in the hydrophobic core, but
not doing so would leave a hole in the core of the protein – clearly
an energetically expensive proposition. Additionally, another resi-
due lining the CoA binding tunnel, Leu220 in E. coli and Leu219 in
H. inﬂuenzae FabH, precludes the Phe in question to take up the rot-
amer that would point the side chain within the cleft. Correspond-
ing to Leu220 in E. coli FabH is the smaller side chain Val231 in E.
faecalis protein, which does not interfere with Phe312 side chain
pointing inside the cleft. Thus, the FabH sequences in E. faecalis,
S. aureus and M. tuberculosis on one hand and E. coli and H. inﬂuen-
zae on the other, dictate signiﬁcant differences in the shape of the
deep end of the substrate-binding site by forcing the individual
amino acid side-chains to adopt particular rotamers.
It is evident that the pair of residues at positions equivalent to
Phe226 and Val231 in E. faecalis protein must determine the rot-
amer conformation of the residue at the position equivalent to
the Phe312, and in the process determine the shape of the active
site cleft (Fig. 5). Based on this premise, we looked at the sequences
of some of the important Gram-positive and -negative pathogens
to see if there is a trend vis-à-vis the Phe residue that changes
the shape of the CoA binding site. Interestingly, all Gram-positive
organisms we looked at retain the Phe226 of the E. faecalis enzyme,
leading to the prediction that they must have a CoA binding site
that is analogous to the E. faecalis FabH, by virtue of the Phe312-
equivalent pointed within the binding site (Fig. 4). The FabH
sequences from the Gram-negative organisms, however, do not
present the same consistent pattern. The substrate-binding site
for the Gram-negative T. thermophilus FabH clearly resembles that
of Gram-positive organisms rather than the binding sites of the
Gram-negative E. coli and H. inﬂuenzae FabH. This is consistent
with the sequence-structure correlation drawn above for Gram-po-
sitive organisms. While the sequences of Salmonella typhimurium,
Helicobacter pylori and Vibrio cholerae FabH strongly suggest that
their CoA binding clefts have structures very similar to the crystal-
lographically observed sites in E. coli and H. inﬂuenzae FabH, those
of Rickettsia rickettsii, Yersinia pestis and Neisseria meningitides sug-
gest that they look more like FabH from other Gram-positive
organisms.
Interestingly, the prediction concerning the shape of the sub-
strate-binding pocket of FabH from different bacterial species par-
allels the experimental evidence that a number of these bacterial
species can use branched chain primers in order to produce
branched chain fatty acids [17,18]. For example, S. aureus, most
Bacilli, Streptococcus pneumoniae, Listeria monocytogenes are known
to synthesize branched chain fatty acids [17]. B. subtilis, S. glauces-
cens, Streptomyces coelicolor and S. pneumoniae FabH have been
shown to be active in the presence of iso-butyryl CoA [5,18,19].
Protein sequences of S. coelicolor and S. glaucescens clearly suggest
that their substrate-binding pockets are akin to the substrate-bind-
ing pocket of E. faecalis enzyme. On the other hand, E. coli FabH is
known to be selective for acetyl-CoA, initiating the synthesis of
straight chain fatty acids [8,19–21].
This analysis of the binding site also explains the reported dif-
ferences in cross-genus activity [15] of some of the inhibitors that
are analogs of the benzoylamino-benzoic acid derivatives (Fig. 2).
These inhibitors are nearly equipotent against E. faecalis and
S. pyogenes FabH as would be predicted by the analysis presented
here (Fig. 4). However, they are largely ineffective against H. inﬂu-enzae FabH. When docked into the H. inﬂuenzae FabH structure, the
benzoic acid group of the compound sterically clashes into the
Phe303 (the equivalent of Phe312 in E. faecalis enzyme) due to
its different rotamer conformation. The compounds retain some
activity against S. aureus enzyme but weaker than expected based
on the binding site similarities. This is again due to steric conﬂict
with the equivalent Ph298 at the base of the binding site. Phe298
sidechain in S. aureus FabH is rotated so as to occlude the bulky
benzoic acid group.
In a previous attempt to explain the substrate speciﬁcities of
priming ketosynthases, which included FabH and its homolog
ZhuH, it was suggested that the length of the loop L9 along with
the identity of the residue at the position equivalent to Met92 of
E. faecalis FabH might inﬂuence the shape of the acyl binding pock-
et thereby modulating the substrate speciﬁcity [22]. Although this
is a possibility that cannot be ruled out, in light of the crystallo-
graphic data for FabH from different species with varying lengths
of loops L9 and showing minimal divergence in the shapes of their
acyl binding pockets, we tend to favor alternative explanation pre-
sented here. Moreover, ZhuH sequence and structure analysis and
its ability to use branched chain substrate is consistent with the
hypothesis proposed here (Fig. 4).
As shown here, perfect conservation of the amino acid residues
that constitute the target site used for inhibitor design is not en-
ough to assure the perfect conservation of its three-dimensional
architecture. It is likely that the identities of residues that are a
layer (or two) removed from the immediate vicinity of the target
site might affect its shape by subtly changing the rotamer confor-
mation of the residues lining the target site. In such a scenario, as
in FabH, the daunting challenge would be to come up with a
small molecule inhibitor of the enzyme that maintains the shape
complementarity with the general architecture of the substrate-
binding clefts of the enzymes from different species, while at
the same time keeping subtle differences in active site architec-
tures from negatively inﬂuencing the potency of the small
molecule.Acknowledgements
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